1. Home
  2. BCDA vs UGRO Comparison

BCDA vs UGRO Comparison

Compare BCDA & UGRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCDA
  • UGRO
  • Stock Information
  • Founded
  • BCDA N/A
  • UGRO 2014
  • Country
  • BCDA United States
  • UGRO United States
  • Employees
  • BCDA N/A
  • UGRO N/A
  • Industry
  • BCDA Biotechnology: Pharmaceutical Preparations
  • UGRO Industrial Specialties
  • Sector
  • BCDA Health Care
  • UGRO Consumer Discretionary
  • Exchange
  • BCDA Nasdaq
  • UGRO Nasdaq
  • Market Cap
  • BCDA 7.9M
  • UGRO 8.8M
  • IPO Year
  • BCDA N/A
  • UGRO N/A
  • Fundamental
  • Price
  • BCDA $2.84
  • UGRO $0.73
  • Analyst Decision
  • BCDA Strong Buy
  • UGRO Strong Buy
  • Analyst Count
  • BCDA 1
  • UGRO 2
  • Target Price
  • BCDA $25.00
  • UGRO $5.63
  • AVG Volume (30 Days)
  • BCDA 55.7K
  • UGRO 129.8K
  • Earning Date
  • BCDA 03-26-2025
  • UGRO 03-26-2025
  • Dividend Yield
  • BCDA N/A
  • UGRO N/A
  • EPS Growth
  • BCDA N/A
  • UGRO N/A
  • EPS
  • BCDA N/A
  • UGRO N/A
  • Revenue
  • BCDA $71,000.00
  • UGRO $70,320,066.00
  • Revenue This Year
  • BCDA N/A
  • UGRO $17.15
  • Revenue Next Year
  • BCDA N/A
  • UGRO $21.76
  • P/E Ratio
  • BCDA N/A
  • UGRO N/A
  • Revenue Growth
  • BCDA N/A
  • UGRO 12.08
  • 52 Week Low
  • BCDA $1.63
  • UGRO $0.60
  • 52 Week High
  • BCDA $8.85
  • UGRO $2.84
  • Technical
  • Relative Strength Index (RSI)
  • BCDA 67.71
  • UGRO 36.76
  • Support Level
  • BCDA $2.27
  • UGRO $0.66
  • Resistance Level
  • BCDA $2.78
  • UGRO $1.12
  • Average True Range (ATR)
  • BCDA 0.26
  • UGRO 0.12
  • MACD
  • BCDA 0.04
  • UGRO 0.01
  • Stochastic Oscillator
  • BCDA 86.90
  • UGRO 25.05

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

About UGRO urban-gro Inc.

Urban-gro Inc is an integrated professional services and construction design-build firm. Its business focuses predominantly on providing fee-based knowledge-based services as well as the value-added reselling of equipment. The company offers value-added architectural, engineering, systems procurement and integration, and construction design-build solutions to customers operating in the controlled environment agriculture (CEA) and industrial and other commercial (Commercial) sectors. It derives revenue predominately from the sale of equipment systems, services, construction design-build, and other various immaterial contracts with customers.

Share on Social Networks: